Literature DB >> 29708129

The direction of travel to better outcomes for patients with oesophago-gastric cancer.

Ruth Elizabeth Langley1.   

Abstract

Entities:  

Year:  2018        PMID： 29708129      PMCID： PMC5906216          DOI： 10.21037/jtd.2018.03.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Authors:  Kei Muro; Hyun Cheol Chung; Veena Shankaran; Ravit Geva; Daniel Catenacci; Shilpa Gupta; Joseph Paul Eder; Talia Golan; Dung T Le; Barbara Burtness; Autumn J McRee; Chia-Chi Lin; Kumudu Pathiraja; Jared Lunceford; Kenneth Emancipator; Jonathan Juco; Minori Koshiji; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2016-05-03       Impact factor: 41.316

2.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

3.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

4.  Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Authors:  Eirini Pectasides; Matthew D Stachler; Sarah Derks; Yang Liu; Steven Maron; Adam J Bass; Daniel V Catenacci; Mirazul Islam; Lindsay Alpert; Heewon Kwak; Hedy Kindler; Blase Polite; Manish R Sharma; Kenisha Allen; Emily O'Day; Samantha Lomnicki; Melissa Maranto; Rajani Kanteti; Carrie Fitzpatrick; Christopher Weber; Namrata Setia; Shu-Yuan Xiao; John Hart; Rebecca J Nagy; Kyoung-Mee Kim; Min-Gew Choi; Byung-Hoon Min; Katie S Nason; Lea O'Keefe; Masayuki Watanabe; Hideo Baba; Rick Lanman; Agoston T Agoston; David J Oh; Andrew Dunford; Aaron R Thorner; Matthew D Ducar; Bruce M Wollison; Haley A Coleman; Yuan Ji; Mitchell C Posner; Kevin Roggin; Kiran Turaga; Paul Chang; Kyle Hogarth; Uzma Siddiqui; Andres Gelrud; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah Reed; Greg Gydush; Denisse Rotem; Jon Davison; Yu Imamura; Viktor Adalsteinsson; Jeeyun Lee
Journal:  Cancer Discov       Date:  2017-10-04       Impact factor: 39.397

5.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Authors:  Elizabeth C Smyth; Andrew Wotherspoon; Clare Peckitt; David Gonzalez; Sanna Hulkki-Wilson; Zakaria Eltahir; Matteo Fassan; Massimo Rugge; Nicola Valeri; Alicia Okines; Madeleine Hewish; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; David Cunningham
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 33.006

6.  Integrated genomic characterization of oesophageal carcinoma.

Authors: 
Journal:  Nature       Date:  2017-01-04       Impact factor: 49.962

7.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

8.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

Review 9.  Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.

Authors:  C Gilson; S Chowdhury; M K B Parmar; M R Sydes
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-10-25       Impact factor: 4.126

10.  Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Authors:  Maria Secrier; Xiaodun Li; Nadeera de Silva; Matthew D Eldridge; Gianmarco Contino; Jan Bornschein; Shona MacRae; Nicola Grehan; Maria O'Donovan; Ahmad Miremadi; Tsun-Po Yang; Lawrence Bower; Hamza Chettouh; Jason Crawte; Núria Galeano-Dalmau; Anna Grabowska; John Saunders; Tim Underwood; Nicola Waddell; Andrew P Barbour; Barbara Nutzinger; Achilleas Achilleos; Paul A W Edwards; Andy G Lynch; Simon Tavaré; Rebecca C Fitzgerald
Journal:  Nat Genet       Date:  2016-09-05       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.